Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

NCT00850993 is registered in ClinicalTrials.gov with InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company as lead sponsor.

NCT NCT00850993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00850993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2008
Completion date
May 31, 2012
Enrollment
58 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

hyperbilirubinemia, neonatal